Ascendis Pharma A/S
ASND · XNASCIK 1612042fmd_0P1BMDFDJJT75N4EHK1DJ44R3TManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 38 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 5 | 2 | 11 | 13 | 7 | 8 | 51 | 267 | 364 | 720 |
| Cost of revenue | – | – | – | 0 | 0 | 4 | 12 | 44 | 44 | 95 |
| Gross profit | – | – | – | 13 | 7 | 4 | 39 | 222 | 319 | 625 |
| Research and development | 66 | 100 | 140 | 192 | 261 | 296 | 380 | 413 | 307 | 304 |
| Selling, general and administrative | 12 | 13 | 25 | 48 | 77 | 160 | 221 | 264 | 291 | 458 |
| Operating income | (73) | (112) | (155) | (227) | (331) | (452) | (562) | (456) | (279) | (136) |
| Interest expense | 3 | 14 | 0 | 1 | 81 | 4 | 50 | 44 | 100 | 207 |
| Income before taxes | (69) | (124) | (130) | (218) | (419) | (384) | (578) | (474) | (373) | (213) |
| Income tax expense | (0) | (0) | (0) | (0) | (0) | (0) | 5 | 7 | 5 | 15 |
| Net income from continuing operations | (69) | (124) | (130) | (218) | (419) | (384) | (583) | (481) | (378) | (228) |
| Net income | (69) | (124) | (130) | (218) | (419) | (384) | (583) | (481) | (378) | (228) |